BIIB 250411 125.00P(BIIB250411P125000) Stock Price Today

US OptionsDetailed Quotes

BIIB250411P125000

Watchlist

7.90
+5.70+259.09%

15min DelayClose Apr 7 16:00 ET

7.93High7.80Low

Intraday

5D
Daily

News

Argus Research Downgrades Biogen(BIIB.US) to Hold Rating
Moomoo NewsApr 4 19:32 ET · Ratings
RFK Jr. to Reinstate 20% of HHS Staff Laid off After DOGE Errors
Seeking AlphaApr 4 11:13 ET
Argus Research Downgrades Biogen to Hold
BenzingaApr 4 11:03 ET
Biogen Analyst Ratings
BenzingaApr 4 10:59 ET · Ratings
Biogen Stock Hits 52-week Low at $128 Amid Challenges
InvestingApr 4 10:16 ET
Express News | Shares of Merck Down 1%, Biogen Down 2.1%, Pfizer Down 1.7%, Eli Lilly Down 3.6% and Abbvie Down 1.3%
ReutersApr 4 09:37 ET

Comments

Teddy123

Apr 1 19:55

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

$Organon & Co (OGN.US)$ $Biogen (BIIB.US)$
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal

Teddy123

Mar 24 19:34

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

$Biogen (BIIB.US)$
Biogen's Bold Move: 580,000 sq ft Innovation Powerhouse to Transform Kendall Square Research Hub

Teddy123

Mar 11 19:35

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

$Biogen (BIIB.US)$
Biogen's Breakthrough Drug Enters Final Testing Phase for Critical Kidney Transplant Complication

ColdJoke

Mar 7 23:56

confirmed bottom

$Biogen (BIIB.US)$ confirmed technical bottom

thoughtful Bat_8163

Feb 12 22:41

$Biogen (BIIB.US)$ Leqembi sale 81 m, last quarter was 51 m. more than 50% higher. Third quarter (51m) was 30% higher than the second. Even though it is just a small percentage of the total revenue (2.46 billion), the sale of Leqembinis is accelerating